Phase I/II Trial of Oral Erlotinib (Tarceva, OSI-774) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma

Trial Profile

Phase I/II Trial of Oral Erlotinib (Tarceva, OSI-774) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Dec 2012 Planned end date changed from 1 Mar 2012 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 08 Sep 2008 Planned end date changed from 1 Mar 2008 to 1 Mar 2012, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top